title: Update on reslizumab for eosinophilic asthma.
abstract: BACKGROUND
  Patients with severe eosinophilic asthma have an unmet need for novel and efficacious treatments. Reslizumab is one of the three monoclonal antibodies targeting the IL-5 pathway and has been found in Phase IIIb clinical trials to reduce asthma exacerbations, control asthma-related symptoms and improve pulmonary function in patients with eosinophilic asthma.
  
  
  METHODS
  In this article, we discuss the results of asthma clinical trials using reslizumab, beginning with a discussion of the relationship between eosinophils, IL-5 and asthma. We conducted PubMed searches using the terms 'reslizumab', 'anti-IL-5', 'eosinophilic asthma', 'IL-5 asthma'. We also searched ClinicalTrials.gov for 'reslizumab', 'reslizumab asthma', 'SCH 55700', 'SCH 55700 asthma', 'Cinquil' and 'Cinquil asthma'.
  
  
  CONCLUSIONS
  Reslizumab and other anti-IL-5 therapies have seen success in recent trials through more stringent study participant selection targeting eosinophilic inflammation. This selection can now be based on simple blood counts. These drugs have shown a very good safety profile, but long-term safety data are not yet available. Approval for these drugs is eagerly awaited by clinicians and patients alike.
authors.affiliation: a 1 Harvard Medical School , Boston, MA, USA.|b 2 Assistant Director of the Asthma Research Center,Brigham and Women's Hospital , Boston, MA, USA.|c 3 Divisions of Rheumatology, Immunology & Allergy and Pulmonary and Critical Care Medicine , Boston, MA, USA.
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Cardet
authors.affiliation: d 4 Harvard Medical School. Director of Clinical Research, Division of Pulmonary Medicine, Brigham and Women's Hospital , 75 Francis st, Boston, MA 02115, USA +1 61 77 32 81 10 ; +1 61 77 32 74 21 ; eisrael@partners.org.
authors.forename: Elliot
authors.initials: E
authors.lastname: Israel
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D016208:Databases, Factual; D004804:Eosinophils / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D006801:Humans; D015848:Interleukin-5 / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015848:Interleukin-5; C515492:reslizumab
keywords: IL-5; anti-IL-5 therapy; asthma; eosinophil; eosinophilic inflammation; monoclonal antibody; reslizumab